Latest On Seelos Therapeutics, Inc (SEEL):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 14:35 EST | News | Seelos Therapeutics GAAP EPS of -$0.12 misses by $0.02, revenue of $0.81M | N/A |  |
| 2023-03-10 13:11 EST | News | Seelos stock falls on ~$11.2M stock, warrants direct offering | N/A | |
| 2023-02-12 08:37 EST | News | Psychedelic Sunday: Scrutinizing Psychedelic Stocks | N/A | |
| 2023-01-08 20:10 EST | News | Scrutinizing Psychedelic Stocks | N/A | |
| 2022-12-16 09:18 EST | News | Seelos drops 14% after pre-clinical data for Parkinson's disease candidate | N/A | |
| 2022-10-04 21:07 EST | News | Seelos: Data This Year Is Critical | N/A | |
| 2022-08-24 09:27 EST | News | Seelos wins Parkinson’s research grant for gene therapy program | N/A | |
| 2022-06-10 02:56 EST | News | Seelos shares data supporting dementia studies for Parkinson’s candidate | N/A | |
| 2022-05-18 13:02 EST | News | Seelos Therapeutics to get US patent for SLS-007 linked to treating neurodegenerative diseases | N/A | |
| 2022-03-08 19:21 EST | News | Seelos gets acknowledgement letter from Australian regulator for Alzheimer's study | N/A | |
| 2021-12-22 23:42 EST | News | Seelos: FDA Action Makes It Highly Attractive | N/A | |
| 2021-12-06 21:52 EST | News | Seelos Therapeutics secures composition of matter patent in Japan for SLS-007 | N/A | |
| 2021-11-25 03:55 EST | News | Seelos Therapeutics raises $20M in senior convertible notes offering | N/A | |
| 2021-11-25 03:55 EST | News | Seelos Therapeutics jumps 9% on acquisition of license for sublingual ketamine wafers | N/A | |
| 2021-11-15 12:14 EST | News | Warning: SEEL is at high risk of performing badly | N/A | |
| 2021-10-15 20:15 EST | News | DEA calls for increase in production of psychedelics for research - Marijuana Moment | N/A | |
| 2021-10-01 21:01 EST | News | Seelos Therapeutics: Shares Have Finally Found A Floor But Risk Remains | N/A | |
| 2021-09-29 22:55 EST | News | Seelos Therapeutics cools off day after Roth upgrade led to 14% rise | N/A | |
| 2021-09-28 01:20 EST | News | Seelos climbs after Roth Capital upgraded with over threefold rise in price target | N/A | |
| 2021-09-01 10:12 EST | News | Seelos Therapeutics picks internal candidates for CFO and communications chief | N/A | |
| 2021-07-21 23:50 EST | News | Seelos Therapeutics' SLS-005 an Orphan Drug in Europe for amyotrophic lateral sclerosis | N/A | |
| 2021-07-21 23:47 EST | News | Stryker 'premium growth' prompts upgrade, UHC undervalued by 10% and more in analyst action | N/A | |
| 2021-07-21 23:40 EST | News | Seelos: Superior Data, But Early Stage | N/A | |
| 2021-07-21 23:22 EST | News | Seelos Therapeutics makes it to the Russell 2000, Russell 3000 and Russell Microcap Indexes | N/A | |
| 2021-07-21 23:16 EST | News | Vertex initiated at Raymond James, Altimmune price target lowered, and more in analyst action | N/A | |
| 2021-07-21 23:13 EST | News | Seelos doses first patient in part 2 of SLS-002 major depressive disorder study | N/A | |
| 2021-07-21 23:11 EST | News | Seelos Therapeutics posts promising data from SLS-004 rodent study | N/A | |
| 2021-07-21 22:56 EST | News | Interest in "shroom stocks" rises as investors see potential of psychedelics as therapy | N/A | |
| 2021-04-07 21:09 EST | News | Seelos Therapeutics shares 6% higher as BTIG reiterates buy following Aptar deal | N/A | |
| 2021-04-06 08:39 EST | News | Seelos partners with AptarGroup for drug delivery system | N/A | |
| 2021-03-30 12:24 EST | News | Ascendis downgraded at Oppenheimer, Aytu initiated at overweight at Cantor and more in today's analyst action | N/A | |
| 2021-03-16 21:59 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-16 21:59 EST | Earnings Estimate | An EPS average of -$0.44 is estimated for the 2022 year. | Sell | |
| 2021-03-16 21:59 EST | Earnings Estimate | An EPS average of -$0.07 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-03-16 21:59 EST | Analyst Rating | The Analyst Target Price has increased from $9 to $10.67. | Buy | |
| 2021-03-12 10:50 EST | News | Seelos surges as BTIG initiates with Street high target | N/A | |
| 2021-03-12 08:30 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-11 13:48 EST | News | Seelos Therapeutics: SLS-002 For Suicidality Is Very Promising | N/A | |
| 2021-03-10 12:16 EST | Analyst Rating | The Analyst Target Price has increased from $8 to $9. | Buy | |
| 2021-03-06 01:56 EST | News | Seelos completes enrollment in part 1 of SLS-002 suicidal ideation study | N/A | |
| 2021-02-18 21:53 EST | News | Seelos amends the agreement with Vyera Pharmaceuticals | N/A | |
| 2021-01-29 23:28 EST | News | Seelos announces issuance of a patent for trehalose (SLS-005) in Australia | N/A | |
| 2021-01-26 13:08 EST | News | Seelos Therapeutics to raise ~$31M capital in stock offering | N/A | |
| 2021-01-22 19:45 EST | News | Seelos perks up after Japanese patent for SLS-005 | N/A | |
| 2021-01-15 15:17 EST | News | Seelos Therapeutics' patient dosing in SLS-002 study gets underway | N/A | |
| 2021-01-06 10:27 EST | News | Seelos' expects to commence SLS-005 study in rare neurological disease in H1 2021, shares up 6% | N/A | |
| 2020-12-22 08:22 EST | News | Seelos nabs new patent in Israel covering trehalose | N/A | |
| 2020-12-21 14:39 EST | News | Seelos Therapeutics' trehalose nabs Israel patent | N/A | |
| 2020-12-16 11:36 EST | News | Seelos Therapeutics (SEEL) files for $200M mixed shelf, shares down 8% | N/A | |
| 2020-12-15 00:43 EST | News | Seelos raises $10M via convertible debt offering | N/A | |
About Seelos Therapeutics, Inc (SEEL):
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorder and post-traumatic stress disorder; SLS-005, a protein stabilizer for the treatment of Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
General
- Name Seelos Therapeutics, Inc
- Symbol SEEL
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 9
- Last Split Factor1:30
- Last Split Date2019-01-24
- Fiscal Year EndDecember
- IPO Date1999-04-19
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Web URLhttp://seelostherapeutics.com
View More
Valuation
- Trailing PE 0.78
- Price/Sales (Trailing 12 Mt.) 431.84
- Price/Book (Most Recent Quarter) 32.74
- Enterprise Value Revenue 563.13
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.38
- Next Year EPS Estimate -$0.44
- Next Quarter EPS Estimate -$0.07
- Return on Assets -82%
- Return on Equity -1489%
- Earnings Per Share -$0.81
- Revenue Per Share $0
- Gross Profit -10984000
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 303.62 million
- Analyst Target Price $10.67
- Book Value Per Share $0.05
View More
Share Statistics
- Shares Outstanding 73.25 million
- Shares Float 68.1 million
- % Held by Insiders 1338%
- % Held by Institutions 10.09%
- Shares Short 2.58 million
- Shares Short Prior Month 2.44 million
- Short Ratio 0.56
- Short % of Float 4%
- Short % of Shares Outstanding 4%
View More
Technicals
- Beta 2.81
- 52 Week High $4.92
- 52 Week Low $0.42
- 50 Day Moving Average 3.25
- 200 Day Moving Average 1.63
View More
Dividends
- Dividend Date 2019-01-24
- ExDividend Date N/A
- Dividend Yield 0%
View More
Seelos Therapeutics, Inc (SEEL) Dividend Calendar:
SEEL's last dividend payment was made to shareholders on January 24, 2019.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Seelos Therapeutics, Inc (SEEL) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-11 | $N/A | -$0.13 | -$0.08 | -56.06% |
| 2020-09-30 | 2020-11-12 | $N/A | -$0.09 | -$0.08 | -12.5% |
| 2020-06-30 | 2020-08-14 | $N/A | -$0.08 | -$0.14 | 40.74% |
| 2020-03-31 | 2020-05-07 | $N/A | -$0.14 | -$0.22 | 36.36% |
| 2019-12-31 | 2020-03-17 | $N/A | -$0.27 | -$0.17 | -63.64% |
| 2019-09-30 | 2019-11-07 | $375000 | -$0.15 | -$0.12 | -25.42% |
| 2019-06-30 | 2019-08-01 | $N/A | -$0.16 | -$0.15 | -7.13% |
| 2019-03-31 | 2019-05-21 | $N/A | -$1.38 | -$0.20 | -590.45% |
| 2018-12-31 | 2019-03-28 | $N/A | -$1.97 | ||
| 2018-09-30 | 2018-10-31 | $N/A | -$3.58 | ||
| 2018-06-30 | 2018-08-09 | $N/A | -$3.00 | -$3.60 | 16.67% |
| 2018-03-31 | 2018-05-03 | $N/A | -$4.20 | -$3.60 | -16.67% |
| 2017-12-31 | 2018-03-01 | $N/A | -$4.20 | -$4.35 | 3.45% |
| 2017-09-30 | 2017-11-02 | $N/A | -$9.00 | -$4.65 | -93.55% |
| 2017-06-30 | 2017-08-02 | $N/A | -$4.50 | -$4.80 | 6.25% |
| 2017-03-31 | 2017-05-11 | $N/A | -$13.20 | $37.35 | -135.34% |
| 2016-12-31 | 2017-03-13 | $356000 | $0.03 | -$0.14 | 121.43% |
| 2016-09-30 | 2016-11-08 | $4.32 million | -$0.19 | -$0.60 | 68.33% |
| 2016-06-30 | 2016-08-04 | $464000 | -$0.50 | -$0.80 | 37.5% |
| 2016-03-31 | 2016-05-09 | -$0.50 | -$0.87 | 42.53% | |
| 2015-12-31 | 2016-03-09 | $2.63 million | -$0.50 | -$1.10 | 54.55% |
| 2015-09-30 | 2015-11-05 | $1.27 million | -$1.00 | -$1.10 | 9.09% |
| 2015-06-30 | 2015-08-05 | $462000 | -$1.00 | -$1.25 | 20% |
| 2015-03-31 | 2015-05-11 | $475000 | -$1.30 | -$1.00 | -30% |
| 2014-12-31 | 2015-03-16 | $1.91 million | -$0.90 | -$1.20 | 25% |
| 2014-09-30 | 2014-11-10 | $1.9 million | -$0.80 | -$0.97 | 17.53% |
| 2014-06-30 | 2014-08-11 | $5.45 million | $9.00 | -$11.00 | 181.82% |
| 2014-03-31 | 2014-05-12 | $N/A | -$27.00 | -$9.00 | -200% |
| 2013-12-31 | 2014-03-17 | -$12.00 | -$17.00 | 29.41% | |
| 2013-09-30 | 2013-11-08 | $28000 | -$24.00 | -$33.00 | 27.27% |
| 2013-06-30 | 2013-08-14 | $1.19 million | -$42.00 | -$32.00 | -31.25% |
| 2013-03-31 | 2013-05-10 | $1.02 million | -$69.00 | -$39.00 | -76.92% |
| 2012-12-31 | 2013-03-18 | $2.36 million | -$75.00 | -$55.00 | -36.36% |
| 2012-09-30 | 2012-11-08 | $5.15 million | -$27.00 | -$22.50 | -20% |
| 2012-06-30 | 2012-08-09 | $119633 | -$57.00 | -$29.25 | -94.87% |
| 2012-03-31 | 2012-05-10 | $781481 | -$58.88 | ||
| 2011-12-31 | 2012-03-13 | -$66.00 | -$6.00 | -1000% | |
| 2011-09-30 | 2011-11-14 | $799419 | -$32.97 | ||
| 2011-06-30 | 2011-08-15 | $1.6 million | -$117.99 | ||
| 2011-03-31 | 2011-05-13 | -$53.46 | |||
| 2010-12-31 | 2011-03-10 | -$222.00 | -$36.00 | -516.67% | |
| 2010-09-30 | 2010-11-09 | -$61.29 | |||
| 2010-06-30 | 2010-08-12 | -$140.43 | |||
| 2010-03-31 | 2010-05-13 | -$375.57 | |||
| 2009-12-31 | 2010-03-24 | -$1,530.02 | |||
| 2009-09-30 | 2009-11-10 | -$60.39 | |||
| 2009-06-30 | 2009-08-10 | -$75.64 | |||
| 2009-03-31 | 2009-05-11 | $36.52 | |||
| 2008-12-31 | 2009-03-16 | $61.29 | |||
| 2008-09-30 | 2008-11-10 | -$162.99 | |||
| 2008-06-30 | 2008-08-06 | -$90.00 | -$90.00 | 0% | |
| 2008-03-31 | 2008-05-12 | -$90.00 | -$135.00 | 33.33% | |
| 2007-12-31 | 2008-03-12 | -$135.00 | -$67.50 | -100% | |
| 2007-09-30 | 2007-11-14 | -$90.00 | -$90.00 | 0% | |
| 2007-06-30 | 2007-08-14 | -$90.00 | -$90.00 | 0% | |
| 2007-03-31 | 2007-05-10 | -$135.00 | -$135.00 | 0% | |
| 2006-12-31 | 2007-03-26 | -$135.00 | -$90.00 | -50% | |
| 2006-09-30 | 2006-11-09 | -$135.00 | -$90.00 | -50% | |
| 2006-06-30 | 2006-08-09 | -$90.00 | -$90.00 | 0% | |
| 2006-03-31 | 2006-05-09 | -$225.00 | -$180.00 | -25% | |
| 2005-12-31 | 2006-03-17 | -$270.00 | -$225.00 | -20% | |
| 2005-09-30 | 2005-11-09 | -$315.00 | -$360.00 | 12.5% | |
| 2005-06-30 | 2005-08-09 | -$450.00 | -$472.50 | 4.76% | |
| 2005-03-31 | 2005-05-10 | -$402.53 | |||
| 2004-12-31 | 2005-03-03 | -$405.00 | |||
| 2004-09-30 | 2004-11-08 | -$461.60 | |||
| 2004-06-30 | 2004-08-06 | -$443.05 | |||
| 2004-03-31 | 2004-05-06 | -$445.56 | |||
| 2003-12-31 | 2004-03-04 | -$886.37 | |||
| 2003-09-30 | 2003-11-12 | -$396.20 | |||
| 2003-06-30 | 2003-08-12 | -$1,067.26 | |||
| 2003-03-31 | 2003-03-31 | -$543.16 | |||
| 2002-09-30 | 2002-09-30 | -$1,095.36 | |||
| 2002-06-30 | 2002-08-14 | -$1,215.00 | -$900.00 | -35% | |
| 2002-03-31 | 2002-05-14 | -$990.00 | -$1,035.00 | 4.35% | |
| 2001-12-31 | 2002-03-29 | -$1,035.00 | -$585.00 | -76.92% | |
| 2001-09-30 | 2001-11-14 | -$630.00 | -$675.00 | 6.67% | |
| 2001-06-30 | 2001-08-13 | -$630.00 | -$585.00 | -7.69% | |
| 2001-03-31 | 2001-05-14 | -$585.00 | -$1,305.00 | 55.17% | |
| 2000-12-31 | 2001-03-01 | -$630.00 | -$2,767.50 | 77.24% | |
| 2000-09-30 | 2000-11-10 | -$360.00 | -$765.00 | 52.94% | |
| 2000-06-30 | 2000-06-30 | -$598.32 | |||
| 2000-03-31 | 2000-03-31 | -$295.93 | |||
| 1999-09-30 | 1999-09-30 | -$304.83 | |||
| 1999-06-30 | 1999-06-30 | -$479.19 | |||
| 1999-03-31 | 1999-03-31 | -$411.79 | |||
| 1998-09-30 | 1998-09-30 | -$705.66 | |||
| 1998-06-30 | 1998-06-30 | -$741.69 | |||
| 1998-03-31 | 1998-03-31 | -$724.67 |
Seelos Therapeutics, Inc (SEEL) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 2.02 million | N/A | N/A | 11.4 million |
| Income Before Tax | N/A | -4.09 million | N/A | N/A | -10.66 million |
| Selling General Administrative | N/A | 2.07 million | N/A | N/A | 3.13 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | -4.08 million | N/A | N/A | -14.53 million |
| Operating Income | N/A | -4.09 million | N/A | N/A | -14.53 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | -3000 | N/A | N/A | 3.87 million |
| Net Income From Continuing Operations | N/A | -4.09 million | N/A | N/A | -10.66 million |
| Net Income Applicable to Common Shares | -6.45 million | -4.09 million | -3.73 million | -4.83 million | -10.66 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -275000 | -2.65 million | 2.49 million | -1.05 million | 824000 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | 147000 | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 6.38 million | N/A | N/A | 64000 | 8.5 million |
| Change to Operating Activities | -513000 | -1.48 million | -3.93 million | 6.08 million | -231000 |
| Change in Cash | 2.2 million | N/A | N/A | -5.05 million | 5.59 million |
| Total Cash from Operating Activities | -4.18 million | -6.98 million | -6.42 million | -5.12 million | -2.91 million |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 698000 | 878000 | -151000 | 513000 | -282000 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 14.92 million | 3.19 million | N/A | N/A | 11.1 million |
| Total Stockholder Equity | 2.57 million | 6.69 million | N/A | N/A | -7000 |
| Other Current Liabilities | 125000 | 725000 | N/A | N/A | 8.06 million |
| Total Assets | 17.49 million | 9.88 million | N/A | N/A | 11.1 million |
| Common Stock | 54000 | 53000 | 44000 | 44000 | 27000 |
| Other Current Assets | 1.83 million | N/A | N/A | N/A | N/A |
| Retained Earnings | -75.16 million | -68.71 million | -64.62 million | -60.89 million | -56.06 million |
| Other Liabilities | N/A | 200000 | 200000 | 200000 | 325000 |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Cash | 15.66 million | 8.05 million | N/A | N/A | 10.26 million |
| Total Current Liabilities | 7.43 million | 2.84 million | N/A | N/A | 10.78 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | 17.49 million | 9.88 million | N/A | N/A | 11.1 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 2.57 million | 6.69 million | 3.71 million | 6.77 million | -7000 |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | 7.29 million | 147000 | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 3.81 million | 355000 | N/A | N/A | 796000 |
Seelos Therapeutics, Inc (SEEL) Chart:
Seelos Therapeutics, Inc (SEEL) News:
Below you will find a list of latest news for Seelos Therapeutics, Inc (SEEL) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Seelos Therapeutics, Inc (SEEL) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest SEEL Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 34 | $0.6944 |
| Jun 13, 2022 7:59 PM EST | 38 | $0.6944 |
| Jun 13, 2022 7:59 PM EST | 2 | $0.6944 |
| Jun 13, 2022 7:59 PM EST | 5 | $0.6944 |
| Jun 13, 2022 7:59 PM EST | 11 | $0.6944 |
Seelos Therapeutics, Inc (SEEL) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000138/0001136261-20-000138-index.htm |
| 2019-02-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1017491/000000000019001794/0000000000-19-001794-index.htm |
| 2019-02-11 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1017491/000000000019001795/0000000000-19-001795-index.htm |
| 2019-12-03 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1017491/000000000019016033/0000000000-19-016033-index.htm |
| 2020-01-27 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1017491/000000000020000681/0000000000-20-000681-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000089924318029911/0000899243-18-029911-index.htm |
| 2018-11-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000089924318029913/0000899243-18-029913-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000089924319001840/0000899243-19-001840-index.htm |
| 2019-01-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000089924319001841/0000899243-19-001841-index.htm |
| 2019-02-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1017491/000091957419001799/0000919574-19-001799-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000091957420001527/0000919574-20-001527-index.htm |
| 2020-01-16 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000092963820000060/0000929638-20-000060-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000093041319000513/0000930413-19-000513-index.htm |
| 2018-10-31 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000101749118000104/0001017491-18-000104-index.htm |
| 2018-11-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000101749118000108/0001017491-18-000108-index.htm |
| 2018-11-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000101749118000109/0001017491-18-000109-index.htm |
| 2018-11-16 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1017491/000101749118000110/0001017491-18-000110-index.htm |
| 2019-08-30 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1017491/000101749119000002/0001017491-19-000002-index.htm |
| 2020-09-14 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1017491/000101749120000001/0001017491-20-000001-index.htm |
| 2019-03-11 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000110465919013756/0001104659-19-013756-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000110465920013413/0001104659-20-013413-index.htm |
| 2019-01-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000010/0001136261-19-000010-index.htm |
| 2019-01-28 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000011/0001136261-19-000011-index.htm |
| 2019-01-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000012/0001136261-19-000012-index.htm |
| 2019-01-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000013/0001136261-19-000013-index.htm |
| 2019-01-28 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000014/0001136261-19-000014-index.htm |
| 2019-01-30 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000017/0001136261-19-000017-index.htm |
| 2019-01-31 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000019/0001136261-19-000019-index.htm |
| 2019-02-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000033/0001136261-19-000033-index.htm |
| 2019-02-01 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000034/0001136261-19-000034-index.htm |
| 2019-02-06 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000038/0001136261-19-000038-index.htm |
| 2019-02-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000044/0001136261-19-000044-index.htm |
| 2019-02-13 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000061/0001136261-19-000061-index.htm |
| 2019-02-13 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000062/0001136261-19-000062-index.htm |
| 2019-02-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000068/0001136261-19-000068-index.htm |
| 2019-02-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000081/0001136261-19-000081-index.htm |
| 2019-03-01 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000089/0001136261-19-000089-index.htm |
| 2019-03-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000099/0001136261-19-000099-index.htm |
| 2019-03-08 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000100/0001136261-19-000100-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000107/0001136261-19-000107-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000108/0001136261-19-000108-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000109/0001136261-19-000109-index.htm |
| 2019-03-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000110/0001136261-19-000110-index.htm |
| 2019-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000116/0001136261-19-000116-index.htm |
| 2019-03-28 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000121/0001136261-19-000121-index.htm |
| 2019-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000126/0001136261-19-000126-index.htm |
| 2019-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000152/0001136261-19-000152-index.htm |
| 2019-05-15 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000157/0001136261-19-000157-index.htm |
| 2019-05-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000163/0001136261-19-000163-index.htm |
| 2019-05-21 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000166/0001136261-19-000166-index.htm |
| 2019-06-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000177/0001136261-19-000177-index.htm |
| 2019-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000178/0001136261-19-000178-index.htm |
| 2019-06-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000181/0001136261-19-000181-index.htm |
| 2019-07-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000192/0001136261-19-000192-index.htm |
| 2019-08-01 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000209/0001136261-19-000209-index.htm |
| 2019-08-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000215/0001136261-19-000215-index.htm |
| 2019-08-15 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000220/0001136261-19-000220-index.htm |
| 2019-08-23 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000225/0001136261-19-000225-index.htm |
| 2019-08-26 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000228/0001136261-19-000228-index.htm |
| 2019-08-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000232/0001136261-19-000232-index.htm |
| 2019-10-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000239/0001136261-19-000239-index.htm |
| 2019-11-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000264/0001136261-19-000264-index.htm |
| 2019-11-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000265/0001136261-19-000265-index.htm |
| 2019-11-21 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000270/0001136261-19-000270-index.htm |
| 2019-11-27 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000274/0001136261-19-000274-index.htm |
| 2019-12-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000276/0001136261-19-000276-index.htm |
| 2020-01-03 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000006/0001136261-20-000006-index.htm |
| 2020-01-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000007/0001136261-20-000007-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000008/0001136261-20-000008-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000009/0001136261-20-000009-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000010/0001136261-20-000010-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000011/0001136261-20-000011-index.htm |
| 2020-01-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000012/0001136261-20-000012-index.htm |
| 2020-01-22 | S-1 | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000020/0001136261-20-000020-index.htm |
| 2020-01-30 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000026/0001136261-20-000026-index.htm |
| 2020-01-30 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000027/0001136261-20-000027-index.htm |
| 2020-02-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000031/0001136261-20-000031-index.htm |
| 2020-02-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000032/0001136261-20-000032-index.htm |
| 2020-02-05 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000037/0001136261-20-000037-index.htm |
| 2020-02-07 | S-1/A | General form for registration of securities under the Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000041/0001136261-20-000041-index.htm |
| 2020-02-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000042/0001136261-20-000042-index.htm |
| 2020-02-11 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000045/0001136261-20-000045-index.htm |
| 2020-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000050/0001136261-20-000050-index.htm |
| 2020-02-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000053/0001136261-20-000053-index.htm |
| 2020-03-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000077/0001136261-20-000077-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000084/0001136261-20-000084-index.htm |
| 2020-03-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000085/0001136261-20-000085-index.htm |
| 2020-03-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000088/0001136261-20-000088-index.htm |
| 2020-03-17 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000092/0001136261-20-000092-index.htm |
| 2020-03-30 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000095/0001136261-20-000095-index.htm |
| 2020-04-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000098/0001136261-20-000098-index.htm |
| 2020-04-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000103/0001136261-20-000103-index.htm |
| 2020-05-07 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000114/0001136261-20-000114-index.htm |
| 2020-05-15 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000118/0001136261-20-000118-index.htm |
| 2020-05-15 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000119/0001136261-20-000119-index.htm |
| 2020-05-15 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000120/0001136261-20-000120-index.htm |
| 2020-05-19 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000124/0001136261-20-000124-index.htm |
| 2020-05-21 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000131/0001136261-20-000131-index.htm |
| 2020-05-21 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000135/0001136261-20-000135-index.htm |
| 2020-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000137/0001136261-20-000137-index.htm |
| 2020-06-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000138/0001136261-20-000138-index.htm |
| 2020-08-14 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000156/0001136261-20-000156-index.htm |
| 2020-09-08 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000162/0001136261-20-000162-index.htm |
| 2020-09-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000167/0001136261-20-000167-index.htm |
| 2018-11-16 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000114036118043294/0001140361-18-043294-index.htm |
| 2018-11-20 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1017491/000114036118043477/0001140361-18-043477-index.htm |
| 2018-11-30 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000114036118044178/0001140361-18-044178-index.htm |
| 2018-12-06 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000114036118044631/0001140361-18-044631-index.htm |
| 2018-12-26 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000114036118045831/0001140361-18-045831-index.htm |
| 2019-01-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000114036119000397/0001140361-19-000397-index.htm |
| 2019-01-04 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000114036119000398/0001140361-19-000398-index.htm |
| 2019-01-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000114036119001204/0001140361-19-001204-index.htm |
| 2019-01-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000114036119001205/0001140361-19-001205-index.htm |
| 2019-01-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000114036119001465/0001140361-19-001465-index.htm |
| 2019-01-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000114036119001467/0001140361-19-001467-index.htm |
| 2019-04-12 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1017491/000114036119007041/0001140361-19-007041-index.htm |
| 2020-04-01 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1017491/000114036120007717/0001140361-20-007717-index.htm |
| 2020-04-13 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1017491/000114036120008730/0001140361-20-008730-index.htm |
| 2020-05-04 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1017491/000114036120010609/0001140361-20-010609-index.htm |
| 2018-12-14 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1017491/000119312518349990/0001193125-18-349990-index.htm |
| 2018-12-14 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000119312518349992/0001193125-18-349992-index.htm |
| 2018-12-17 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000119312518350191/0001193125-18-350191-index.htm |
| 2018-12-17 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000119312518350192/0001193125-18-350192-index.htm |
| 2018-12-17 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1017491/000119312518350194/0001193125-18-350194-index.htm |
| 2019-04-15 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000119312519106750/0001193125-19-106750-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000119312520033195/0001193125-20-033195-index.htm |
| 2019-02-08 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000138713119000996/0001387131-19-000996-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000138713120001629/0001387131-20-001629-index.htm |
| 2019-01-04 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1017491/000153561019000023/0001535610-19-000023-index.htm |
| 2018-11-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1017491/999999999518002940/9999999995-18-002940-index.htm |
| 2019-02-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1017491/999999999519000237/9999999995-19-000237-index.htm |
| 2019-02-13 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1017491/999999999519000238/9999999995-19-000238-index.htm |
| 2019-12-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1017491/999999999519002729/9999999995-19-002729-index.htm |
| 2020-02-10 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1017491/999999999520000318/9999999995-20-000318-index.htm |
| 2018-11-20 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1017491/999999999718009096/9999999997-18-009096-index.htm |
| 2020-03-06 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1017491/999999999720001139/9999999997-20-001139-index.htm |
| 2020-09-18 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1017491/999999999720004692/9999999997-20-004692-index.htm |
Seelos Therapeutics, Inc (SEEL) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Seelos Therapeutics, Inc (SEEL). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 1338%Institutional Ownership: 1009%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-01-24 | Raj Mehra | Officer | Buy | 3,081,546.00 | 3,081,546.00 | https://www.sec.gov/Archives/edgar/data/1017491/000113626119000011/0001136261-19-000011-index.htm | ||
| 2020-02-13 | Raj Mehra | Officer | Buy | 133,333.00 | 0.75 | 99,999.75 | 3,214,879.00 | https://www.sec.gov/Archives/edgar/data/1017491/000113626120000053/0001136261-20-000053-index.htm |